HubSpot (Cambridge), software for inbound marketing and website personalization. Seeking in IPO: $100 million. Read more: HubSpot files for $100 million IPO (Pictured at center is chief executive Brian Halligan)
Syndax Pharmaceuticals (Waltham), a treatment for patients with therapy-resistant cancers. Company had previously filed its plans for going public, then postponed the IPO in June, but has now refiled its plans with new terms. Seeking in IPO: $74 million. Read more: IPO window shuts for two Massachusetts biotech companies
We’re two-thirds of the way into 2014, and Massachusetts has already blown past last year in terms of IPOs by innovation-related companies. And more could be on the way soon.
Click through the gallery above to see the seven local tech and biotech firms looking to go public in coming months. The IPOs are ordered by dollar amount being sought.
For a look at the Boston-area, innovation-economy companies that have already pulled off IPOs in 2014, there’s now an infographic for that. The total for the year so far is 17 IPOs in tech and biotech from Massachusetts, versus 10 in 2013.
Editor’s note: This post has been modified since it was first posted, to add Tokai Pharmaceuticals. Images of IPO and coins and of Massachusetts map via Shutterstock.
Replacing the founder of a publicly traded company can be a tough assignment for any executive. Walking into that job right after getting an unsolicited offer to buy the company, however, is a special kind of fun.
That’s been the story of the past few months for Mohamad Ali, the chief executive of Carbonite.
Today's typical biotech tour may not include a swing through the lab — because there isn’t one. Chief executives now brag about the cost savings and flexibility of outsourcing everything from the design of a new drug to supervision of clinical trials to eventual manufacturing.
“The only lab equipment we have here is the sink in the restroom,” says Tom Hughes, chief executive of Zafgen.
A decade ago, if you toured a biotech company in Cambridge, you would don plastic safety glasses and be shown through a brand-spanking-new lab, full of white-coated scientists monitoring experiments. The chief executive would boast about the sophisticated equipment, like imaging systems that could see a tumor shrink inside a rat, and how it would help them bring a new drug to market more quickly.
If you haven't been following the breakup of the 35-year-old venture capital firm Atlas Venture, which once invested in both tech and biotech, partner Peter Barrett sums it up this way: "In this divorce, the life sciences side kept the name, and the tech side got the house." So Atlas's team of tech investors is casting about for a new name, but staying in East Cambridge. And the biotech crew, still known as Atlas, just moved into new offices yesterday atop 400 Technology Square in Cambridge, midway between the Kendall and Central stations on the Red Line.